274 Different Pipelines Molecular Targeted Cancer Therapies Have Been Identified Read More inside the Pipeline/Commercial Insight.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c44205) has announced the addition of Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies - More Drugs on the Market, More Targets in the Pipeline to their offering Cancer treatment continues to embrace the inclusion of molecular targeted therapies (MTT MTT 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide MTT Machine Tool Technology MTT Microwave Theory and Techniques MTT Mobile Task Team MTT Multi-Table Tournament (poker) ) into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge. Scope of this title: * Seven major pharmaceutical market sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. from 2005 to 2015 for approved molecular targeted therapies and key pipeline candidates * Review of the current targeted therapies market, including profiles, product-specific assumptions and events over the forecasted period * Research and analysis of the targeted therapies pipeline with in-depth clinical and commercial assessment of Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA candidates, plus expert opinion * Examination of product pipeline by phase, mode of action, indication, drug class and developer, plus two commercial impact case studies Highlights of this title: In 2005, the MTT market was worth $7.5 billion and the forecast sales of already marketed drugs in this class are expected to grow to $25.2 billion by 2015, at a CAGR CAGR See: Compound Annual Growth Rate of 12.9%. This growth will be driven mainly by Genentech/Roches Rituxan, Herceptin and Avastin as well as Novartis Gleevec, all of which have already reached blockbuster block·bust·er n. 1. Something, such as a film or book, that sustains widespread popularity and achieves enormous sales. 2. A high-explosive bomb used for demolition purposes. 3. status. 274 different pipeline MTTs have been identified. The introduction of current late-phase candidates, including the pre-registered agents Tykerb (lapatinib; GlaxoSmithKline) and Zolinza (vorinostat; Merck), will further increase the markets total value by $3.8 billion, enabling the targeted therapies market to reach $29.1 billion in 2015. The rise in cost of cancer treatment is unsustainable with growing pharmacoeconomic pressures challenging healthcare payers globally. To counter these hurdles, developers must become more effective at communicating the value of their products. To this end, a comprehensive understanding of the targeted therapies market and pipeline is critical. Reasons to order your copy: * Acquire a detailed appreciation and impartial Favoring neither; disinterested; treating all alike; unbiased; equitable, fair, and just. perspective of the targeted cancer therapies market as a whole * Consider and react to the specific events influencing the future potential of marketed and pipeline targeted therapies * Gain an insight into the emerging clinical, developmental and commercial challenges and opportunities facing key developmental and marketed MTT drugs Chapter Outline: Chapter 1. Executive summary Chapter 2. Pipeline overview Chapter 3. Pipeline dynamics Chapter 4. Market definition & pipeline classification Chapter 5. Marketed products forecast analysis Chapter 6. Pipeline angiogenesis inhibitors angiogenesis inhibitor Oncology A chemotherapy adjuvant which inhibits the angiogenesis required for tumor growth and survive, especially for metastastatic tumors See CAI, CM101, IFN-alpha, IL-12, Marimastat, Pentosan polysulfate, Platelet factor 4, Thalidomide, TNP-470. analysis & forecasts Chapter 7. Pipeline single-target signal transduction Signal transduction The transmission of molecular signals from a cell's exterior to its interior. Molecular signals are transmitted between cells by the secretion of hormones and other chemical factors, which are then picked up by different cells. inhibitors analysis & forecasts Chapter 8. Pipeline multi-targeted inhibitors analysis & forecasts Chapter 9. Pipeline cell cycle and apoptosis apoptosis or programmed cell death Mechanism that allows cells to self-destruct when stimulated by the appropriate trigger. It may be initiated when a cell is no longer needed, when a cell becomes a threat to the organism's health, or for other reasons. targeted agents analysis & forecasts Chapter 10. Pipeline epigenetic epigenetic /epi·ge·net·ic/ (-je-net´ik) 1. pertaining to epigenesis. 2. altering the activity of genes without changing their structure. modulators analysis & forecasts Chapter 11. Pipeline immunomodulatory and immunoconjugated therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. analysis & forecasts Chapter 12. Commercial impact & lifecycle management: case studies APPENDIX MARKET DATA & MAJOR BRAND KEY FACTS APPENDIX B SALES FORECASTS APPENDIX C List of Tables List of Figures For more information visit http://www.researchandmarkets.com/reports/c44205 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion